Safety of adalimumab in inflammatory bowel disease: Insights from a clinical cohort
Real-world data on the safety of adalimumab are essential for ongoing pharmacovigilance, while long-term evidence remains limited. This study aimed to evaluate adverse events (AEs) and their temporal patterns in a cohort of patients with inflammatory bowel disease (IBD). A retrospective observational study included 217...